An anticancer therapy-elicited immunosurveillance system that eliminates tetraploid cells

One of the driving forces of oncogenesis is tetraploidy, a duplication of the DNA content that, upon asymmetric cell division or progressive chromosome loss, can originate aneuploidy. Recent findings from our group indicate the existence of an immunosurveillance system that eliminates tetraploid can...

Descripción completa

Detalles Bibliográficos
Autores principales: Senovilla, Laura, Vitale, Ilio, Martins, Isabelle, Kepp, Oliver, Galluzzi, Lorenzo, Zitvogel, Laurence, Castedo, Maria, Kroemer, Guido
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2013
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3583917/
https://www.ncbi.nlm.nih.gov/pubmed/23482968
http://dx.doi.org/10.4161/onci.22409
_version_ 1782475505954455552
author Senovilla, Laura
Vitale, Ilio
Martins, Isabelle
Kepp, Oliver
Galluzzi, Lorenzo
Zitvogel, Laurence
Castedo, Maria
Kroemer, Guido
author_facet Senovilla, Laura
Vitale, Ilio
Martins, Isabelle
Kepp, Oliver
Galluzzi, Lorenzo
Zitvogel, Laurence
Castedo, Maria
Kroemer, Guido
author_sort Senovilla, Laura
collection PubMed
description One of the driving forces of oncogenesis is tetraploidy, a duplication of the DNA content that, upon asymmetric cell division or progressive chromosome loss, can originate aneuploidy. Recent findings from our group indicate the existence of an immunosurveillance system that eliminates tetraploid cancer cells. We surmise that tetraploidy-inducing chemotherapeutic agents may elicit potent anticancer responses by re-activating this immunosurveillance system.
format Online
Article
Text
id pubmed-3583917
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Landes Bioscience
record_format MEDLINE/PubMed
spelling pubmed-35839172013-03-11 An anticancer therapy-elicited immunosurveillance system that eliminates tetraploid cells Senovilla, Laura Vitale, Ilio Martins, Isabelle Kepp, Oliver Galluzzi, Lorenzo Zitvogel, Laurence Castedo, Maria Kroemer, Guido Oncoimmunology Author's View One of the driving forces of oncogenesis is tetraploidy, a duplication of the DNA content that, upon asymmetric cell division or progressive chromosome loss, can originate aneuploidy. Recent findings from our group indicate the existence of an immunosurveillance system that eliminates tetraploid cancer cells. We surmise that tetraploidy-inducing chemotherapeutic agents may elicit potent anticancer responses by re-activating this immunosurveillance system. Landes Bioscience 2013-01-01 /pmc/articles/PMC3583917/ /pubmed/23482968 http://dx.doi.org/10.4161/onci.22409 Text en Copyright © 2013 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Author's View
Senovilla, Laura
Vitale, Ilio
Martins, Isabelle
Kepp, Oliver
Galluzzi, Lorenzo
Zitvogel, Laurence
Castedo, Maria
Kroemer, Guido
An anticancer therapy-elicited immunosurveillance system that eliminates tetraploid cells
title An anticancer therapy-elicited immunosurveillance system that eliminates tetraploid cells
title_full An anticancer therapy-elicited immunosurveillance system that eliminates tetraploid cells
title_fullStr An anticancer therapy-elicited immunosurveillance system that eliminates tetraploid cells
title_full_unstemmed An anticancer therapy-elicited immunosurveillance system that eliminates tetraploid cells
title_short An anticancer therapy-elicited immunosurveillance system that eliminates tetraploid cells
title_sort anticancer therapy-elicited immunosurveillance system that eliminates tetraploid cells
topic Author's View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3583917/
https://www.ncbi.nlm.nih.gov/pubmed/23482968
http://dx.doi.org/10.4161/onci.22409
work_keys_str_mv AT senovillalaura ananticancertherapyelicitedimmunosurveillancesystemthateliminatestetraploidcells
AT vitaleilio ananticancertherapyelicitedimmunosurveillancesystemthateliminatestetraploidcells
AT martinsisabelle ananticancertherapyelicitedimmunosurveillancesystemthateliminatestetraploidcells
AT keppoliver ananticancertherapyelicitedimmunosurveillancesystemthateliminatestetraploidcells
AT galluzzilorenzo ananticancertherapyelicitedimmunosurveillancesystemthateliminatestetraploidcells
AT zitvogellaurence ananticancertherapyelicitedimmunosurveillancesystemthateliminatestetraploidcells
AT castedomaria ananticancertherapyelicitedimmunosurveillancesystemthateliminatestetraploidcells
AT kroemerguido ananticancertherapyelicitedimmunosurveillancesystemthateliminatestetraploidcells
AT senovillalaura anticancertherapyelicitedimmunosurveillancesystemthateliminatestetraploidcells
AT vitaleilio anticancertherapyelicitedimmunosurveillancesystemthateliminatestetraploidcells
AT martinsisabelle anticancertherapyelicitedimmunosurveillancesystemthateliminatestetraploidcells
AT keppoliver anticancertherapyelicitedimmunosurveillancesystemthateliminatestetraploidcells
AT galluzzilorenzo anticancertherapyelicitedimmunosurveillancesystemthateliminatestetraploidcells
AT zitvogellaurence anticancertherapyelicitedimmunosurveillancesystemthateliminatestetraploidcells
AT castedomaria anticancertherapyelicitedimmunosurveillancesystemthateliminatestetraploidcells
AT kroemerguido anticancertherapyelicitedimmunosurveillancesystemthateliminatestetraploidcells

Ejemplares similares